Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical LDE225 in sporadic superficial and nodular BCC
NCT01033019Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in basal cell carcinoma (BCC) comparing LDE225 0.75% with Vehicle (2 arms). Primary endpoint: Clinical Evaluation of sBCCs Tumors at Day 43. Started Dec 2009; status: terminated.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT01033019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01033019.